21st Century Oncology has postponed its IPO, citing unfavorable market conditions. Majority owned by Vestar Capital Partners, the company had previously planned to sell shares on the NYSE under the symbol ICC, with an estimated price range between $14 and $16 per share. On Wednesday, it revised its price expectations downward to be between $8 and $10 a share. Operating a network of around 304 cancer treatment centers including 163 radiation therapy centers, the company boasts around 671 physicians in various oncology fields. Vestar took the company private for $1.1 billion in 2008.